Why Is ADMA Biologics (ADMA) Stock Down -12% Today?
Key Takeaways
- Shares of ADMA are declining approximately 12% in Wednesday's session, extending a steep two-day selloff
- The primary catalyst is a short-seller research report published by Culper Research on March 24, 2026, alleging that ADMA engaged in channel stuffing to artificially inflate revenue growth
- Culper's analysis estimates ADMA's true 2025 revenues actually declined 3% year-over-year, versus the company's reported 20% growth
- Key evidence cited includes a surge in days sales outstanding from 43 to 113 days in 2025, and a $121 million gap between third-party ASCENIV provider sales data and ADMA's reported revenues
- ADMA Biologics responded on March 25 with a press release calling the report "misleading, false, and inaccurate"
- Traders are watching for any regulatory scrutiny, analyst revisions, and further company disclosures in the near term
Opening Summary
ADMA Biologics, Inc. (ADMA) is a U.S.-based, end-to-end commercial biopharmaceutical company specializing in manufacturing, marketing, and developing specialty plasma-derived biologics, with its lead product ASCENIV targeting immunodeficient patients at risk for infection. Shares are down approximately 12% intraday on Wednesday, March 25, 2026, following an initial drop of more than 9% in Tuesday's session when Culper Research first released its bearish short report. The prior close stood at approximately $12.87 after Tuesday's selloff, with shares trading near $11.33 in Wednesday's session. The two-day decline compounds into a roughly 20% drawdown from pre-report levels, driven entirely by the short-seller allegations.
Culper Research Allegations: Channel Stuffing
The central catalyst behind ADMA's sharp price decline is a detailed short-seller report issued by Culper Research on March 24, 2026, in which the firm disclosed a short position and alleged that ADMA's reported revenue growth was driven by a channel stuffing scheme involving an undisclosed related-party distributor. Culper cited a dramatic expansion in days sales outstanding — from 43 days in 2024 to 113 days in 2025 — as a key red flag, arguing that ADMA was shipping product to distributors at an unsustainable pace without corresponding end-user demand. The firm also noted that ADMA reported $231 million in adjusted EBITDA for 2025, yet generated only $50 million in cash from operations, a divergence it characterized as evidence of inflated non-cash revenues.
Revenue Gap and Distributor Concentration
Culper's report presented third-party provider sales data showing that ASCENIV end-user revenues reached $241 million in 2025, compared to ADMA's reported revenues of approximately $363 million — a gap of $121 million, up from just $14 million in 2023. Two distributors, BioCare and CuraScript, accounted for 73% of total revenues and 87% of year-end receivables, a concentration the short seller characterized as unusual and concerning. Anonymous employees at one of those major distributors reportedly told Culper that ADMA offered rebates and extended payment terms up to 120 days to incentivize excess ASCENIV inventory stocking, with the distributor carrying four to six months of supply versus the industry-standard 30 days.
ADMA's Rebuttal
ADMA Biologics pushed back aggressively on March 25, 2026, issuing an official press release via GlobeNewswire that described the Culper report as containing "misleading, false, and inaccurate statements." The company noted that Culper Research is a known short-seller that has published negative reports on other public companies after taking short positions, suggesting a financial motive behind the allegations. ADMA maintained that the report "relied on selective use of data" and did not accurately represent the company's financial position or the commercial performance of ASCENIV. However, the denial has not been sufficient to halt selling pressure, as investors appear to be pricing in the uncertainty around these serious accounting allegations ahead of any independent review.
Market Context and Trading Activity
ADMA's two-day selloff has occurred on significantly elevated volume, consistent with institutional repositioning following a high-profile negative catalyst. The broader biotechnology sector has not experienced comparable pressure, indicating the move is stock-specific rather than sector-driven. Prior to the Culper report, ADMA was already trading below its 2025 highs, with the stock having shed approximately 15% year-to-date heading into the week. The RSI had moved into oversold territory before this latest leg lower, and the stock is now significantly below its 50-day and 200-day moving averages, a technically bearish setup that could invite further selling if no new positive catalysts emerge.
Trending AI Robots
For traders monitoring volatile situations like the ADMA selloff, Tickeron's Trending AI Robots page offers a curated selection of the platform's top-performing automated trading bots under current market conditions. Tickeron operates hundreds of AI-powered bots covering thousands of tickers, but only those demonstrating the strongest real-time performance metrics — across diverse strategies, timeframes, and traded symbols — are featured in the Trending AI Robots section. Whether a trader is focused on momentum plays, mean reversion, or sector-specific strategies, the bots listed there are filtered for current market relevance. Investors and active traders looking for a data-driven edge in fast-moving markets may find this resource particularly useful.
What Comes Next for ADMA
The most immediate question for ADMA is whether management will provide a more detailed quantitative rebuttal to Culper's specific claims — particularly the third-party provider sales data and the distributor inventory allegations — or whether independent auditors or regulators will weigh in. Analyst coverage will be closely watched; prior to the report, the consensus carried a "Buy" recommendation, but revisions are likely if the channel stuffing allegations gain traction. ADMA had previously announced a $125 million accelerated share repurchase with J.P. Morgan as part of a targeted $200 million return to shareholders in 2026, and how that program proceeds under this cloud of uncertainty will be a key signal for the market. The company has also projected $635 million in revenues for 2026 — a target that will be viewed with significant skepticism until the distributor inventory and receivables questions are resolved.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ADMA's RSI Indicator recovers from oversold territory
The RSI Indicator for ADMA moved out of oversold territory on September 16, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 21 of the 23 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on ADMA as a result. In 73 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for ADMA just turned positive on September 22, 2026. Looking at past instances where ADMA's MACD turned positive, the stock continued to rise in 42 of 50 cases over the following month. The odds of a continued upward trend are 84%.
ADMA moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in 241 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ADMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for ADMA crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for ADMA entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 25 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.147) is normal, around the industry mean (26.453). P/E Ratio (13.407) is within average values for comparable stocks, (42.231). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.058). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (4.170) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics
Industry Biotechnology
Advertisement